Development of neuroimaging-based biomarkers

Tuesday, October 09, 2012 — Concurrent Symposia Session I
3:00 p.m. – 5:00 p.m.	Balcony C

Co-chairs

• Barry Horwitz, NIDCD
• Richard Coppola, NIMH

Program

The three fundamental steps necessary for the clinical management of a brain disorder are (1) detection and diagnosis, (2) treatment, and (3) assessment of treatment response. Biomarkers are important for the first and third of these, and may provide targets for treatment. Importantly, a biomarker refers to the underlying disease state, not to the symptoms of a disorder per se. In this symposium, the focus will be on attempts to develop neuroimaging biomarkers for detection, diagnosis and treatment assessment. In particular, neuroimaging can potentially provide both structural and functional brain biomarkers. Recently, advances in neuroimaging have shifted attention from examining individual brain regions to focusing on brain networks, and neuroimaging biomarker development has followed this shift. Speakers will discuss various uses of neuroimaging biomarkers, as well as some specific applications to neurologic and psychiatric disorders.

What can brain based biomarkers be used for?
Barry Horwitz, NIDCD

fMRI biomarkers for differentiating forms of Conduct Disorder
James Blair, NIMH

Markers of cortical plasticity in antidepressant action
Brian Cornwell, NIMH

State-dependent and disease related variations in functional networks
Silvina Horovitz, NINDS

Tracking brain network changes during training and cognitive remediation
Richard Coppola, NIMH

Next-generation therapeutic avenues for neurodegenerative disease: Targeting Pink1 and Parkin to modulate mitochondrial quality control FARE Award Winner
Samuel Hasson, NINDS

back to top